A Görög1, E Antiga2, M Caproni3, G Cianchini4, D De5, M Dmochowski6, J Dolinsek7,8, K Drenovska9, C Feliciani10, K Hervonen11,12, I Lakos Jukic13, Á Kinyó14, T Koltai15,16, I Korponay-Szabó17,18, A V Marzano19,20, A Patsatsi21, C Rose22,23, T Salmi11,12, E Schmidt24,25, J Setterfield26,27, M Shahid9, C Sitaru28,29, S Uzun30, F Valitutti31, S Vassileva9, S Yayli32, M Sárdy1,33. 1. Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary. 2. Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy. 3. Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, Italy. 4. Department of Dermatology, Cristo Re Hospital, Rome, Italy. 5. Department of Dermatology, Postgraduate Institute of Medical Education Research, Chandigarh, India. 6. Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznań, Poland. 7. Gastroenterology Unit, Department of Pediatrics, University Medical Center Maribor, Maribor, Slovenia. 8. Medical Faculty, University of Maribor, Maribor, Slovenia. 9. Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria. 10. Dermatology Unit Azienda Ospedaliero - Universitaria, Università di Parma, Parma, Italy. 11. Coeliac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. 12. Department of Dermatology, Tampere University Hospital, Tampere, Finland. 13. Department of Dermatology and Venereology, University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia. 14. Department of Dermatology, Venereology and Oncodermatology, University of Pécs Medical School, Pécs, Hungary. 15. Association of European Coeliac Societies, Brussels, Belgium. 16. Hungarian Coeliac Society, Budapest, Hungary. 17. Coeliac Disease Centre, Heim Pál National Paediatric Institute, Budapest, Hungary. 18. Faculty of Medicine, Institute of Paediatrics, University of Debrecen, Debrecen, Hungary. 19. Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 20. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 21. Autoimmune Bullous Diseases Unit, 2nd Dermatology Department, Aristotle University School of Medicine, Thessaloniki, Greece. 22. Dermatopathology Laboratory, Lübeck, Germany. 23. German Coeliac Disease Society e. V., Stuttgart, Germany. 24. Department of Dermatology, University of Lübeck, Lübeck, Germany. 25. Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany. 26. St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 27. Centre for Host Microbiome Interactions, Faculty of Dentistry Oral & Craniofacial Sciences, King's College London, London, UK. 28. Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany. 29. BIOSS Centre for Biological Signalling, University of Freiburg, Freiburg, Germany. 30. Department of Dermatology, Akdeniz University Faculty of Medicine, Antalya, Turkey. 31. Pediatric Unit, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy. 32. Department of Dermatology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey. 33. Department of Dermatology and Allergy, University Hospital of LMU, Munich, Germany.
Abstract
INTRODUCTION: Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten-induced skin disorder characterized by subepidermal granular IgA deposition and a variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management of DH. METHODS: The guidelines were created by small subgroups of a guideline committee consisting of 26 specialists from various medical fields and one patients' representative. The members of the committee then discussed the guidelines and voted for the final version at two consensus meetings. The guidelines were developed under the support of the European Academy of Dermatology and Venereology (EADV) and in collaboration with the European Dermatology Forum (EDF). RESULTS: The guidelines summarize evidence-based and expert-based recommendations (S2 level) for the management of DH (see Appendix). CONCLUSION: These guidelines will improve the quality of management of DH and support dermatologists in their diagnostic and therapeutic decisions.
INTRODUCTION:Dermatitis herpetiformis (DH) is a chronic, pruritic, gluten-induced skin disorder characterized by subepidermal granular IgA deposition and a variable degree of enteropathy identical to that seen in coeliac disease. So far, there has been no European consensus about the management of DH. METHODS: The guidelines were created by small subgroups of a guideline committee consisting of 26 specialists from various medical fields and one patients' representative. The members of the committee then discussed the guidelines and voted for the final version at two consensus meetings. The guidelines were developed under the support of the European Academy of Dermatology and Venereology (EADV) and in collaboration with the European Dermatology Forum (EDF). RESULTS: The guidelines summarize evidence-based and expert-based recommendations (S2 level) for the management of DH (see Appendix). CONCLUSION: These guidelines will improve the quality of management of DH and support dermatologists in their diagnostic and therapeutic decisions.